Omiloxetine

Omiloxetine (omiloextinum, omiloxetino INN)^[1] was a selective serotonin reuptake inhibitor drug candidate that underwent preclinical development by the Spanish pharmaceutical company, Ferrer Internacional, until 2005, when it was abandoned.^[2][3]

Omiloxetine

Clinical data
ATC code	None
Identifiers
IUPAC name 2-[(3R,4S)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-1-piperidinyl]-1-(4-fluorophenyl)ethanone
CAS Number	176894-09-0
PubChem CID	3047803
ChemSpider	2310120
UNII	H8YI0SSF7B
ChEMBL	ChEMBL2105290
CompTox Dashboard (EPA)	DTXSID30170205
Chemical and physical data
Formula	C27H25F2NO4
Molar mass	465.497 g·mol−1
3D model (JSmol)	Interactive image
Density	1.3±0.1 g/cm3
Melting point	228.65 °C (443.57 °F)
Boiling point	587.2 °C (1,089.0 °F)
Solubility in water	0.0015 mg/mL (20 °C)
SMILES Fc1ccc(cc1)C(=O)CN3CC[C@H](c2ccc(F)cc2)[C@H](C3)COc4ccc5OCOc5c4
InChI InChI=1S/C27H25F2NO4/c28-21-5-1-18(2-6-21)24-11-12-30(15-25(31)19-3-7-22(29)8-4-19)14-20(24)16-32-23-9-10-26-27(13-23)34-17-33-26/h1-10,13,20,24H,11-12,14-17H2/t20-,24-/m1/s1 Key:FAHGZANUNVVDFL-HYBUGGRVSA-N

Rafael Foguet also patented Abaperidone.

References

1. "Proposed INN: List 76" (PDF). WHO Drug Information. 10 (4): 212–213. 1996.
2. Terencio J (2005-12-05). "Omiloxetine - Ferrer licensing offer, worldwide". R & D Focus Drug News. Archived from the original on 2016-03-07. Retrieved 2012-05-19.
3. De Lecea C (2003-12-08). "Omiloxetine - Ferrer partnering opportunity, worldwide Ferrer preclinical data". R & D Focus Drug News. Archived from the original on 2016-03-07. Retrieved 2012-05-19.